{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T01:16:40Z","timestamp":1774660600797,"version":"3.50.1"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,2,22]],"date-time":"2018-02-22T00:00:00Z","timestamp":1519257600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["atherosclerosis-journal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1016\/j.atherosclerosis.2018.02.024","type":"journal-article","created":{"date-parts":[[2018,2,17]],"date-time":"2018-02-17T12:42:30Z","timestamp":1518871350000},"page":"120-127","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"special_numbering":"C","title":["Statin utilization and lipid goal attainment in high or very-high cardiovascular risk patients: Insights from Italian general practice"],"prefix":"10.1016","volume":"271","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3786-0883","authenticated-orcid":false,"given":"Marcello","family":"Arca","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Ansell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maurizio","family":"Averna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Fanelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine","family":"Gorcyca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u015eerban R.","family":"Iorga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aldo P.","family":"Maggioni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georges","family":"Paizis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Radovan","family":"Tomic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberico L.","family":"Catapano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2018.02.024_bib1","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.1093\/eurheartj\/ehw334","article-title":"Cardiovascular disease in Europe: epidemiological update 2016","volume":"37","author":"Townsend","year":"2016","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2018.02.024_bib2","series-title":"European Cardiovascular Disease Statistics 2017","author":"Wilkins","year":"2017"},{"key":"10.1016\/j.atherosclerosis.2018.02.024_bib3","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2018.02.024_bib4","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2018.02.024_bib5","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2018.02.024_bib6","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0140-6736(12)60367-5","article-title":"The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials","volume":"380","author":"Mihaylova","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2018.02.024_bib7","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1001\/archinte.166.21.2307","article-title":"Primary prevention of cardiovascular diseases with statin therapy: a meta-analysis of randomized controlled trials","volume":"166","author":"Thavendiranathan","year":"2006","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.atherosclerosis.2018.02.024_bib8","doi-asserted-by":"crossref","first-page":"90","DOI":"10.4236\/ojepi.2012.24014","article-title":"Risk factors distribution and cardiovascular disease prevalence in the Italian population: the CHECK study","volume":"2","author":"Tragni","year":"2012","journal-title":"Open J. Epidemiol."},{"key":"10.1016\/j.atherosclerosis.2018.02.024_bib9","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1016\/j.jacc.2009.10.005","volume":"54","author":"Murphy","year":"2009","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2018.02.024_bib10","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1056\/NEJMoa040583","article-title":"Intensive versus moderate lipid lowering with statins after acute coronary syndromes","volume":"350","author":"Cannon","year":"2004","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2018.02.024_bib11","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa050461","article-title":"Intensive lipid lowering with atorvastatin in patients with stable coronary disease","volume":"352","author":"LaRosa","year":"2005","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2018.02.024_bib12","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.1161\/CIRCULATIONAHA.106.624890","article-title":"Risks associated with statin therapy: a systematic overview of randomized clinical trials","volume":"114","author":"Kashani","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2018.02.024_bib13","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1161\/CIRCOUTCOMES.111.000071","article-title":"Comparative tolerability and harms of individual statins: a study-level network meta-analysis of 246 955 participants from 135 randomized, controlled trials","volume":"6","author":"Naci","year":"2013","journal-title":"Circ. Cardiovasc. Qual. Outcomes"},{"key":"10.1016\/j.atherosclerosis.2018.02.024_bib14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0115270","article-title":"Low rates of both lipid-lowering therapy use and achievement of low-density lipoprotein cholesterol targets in individuals at high-risk for cardiovascular disease across Europe","volume":"10","author":"Halcox","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.atherosclerosis.2018.02.024_bib15","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-013255","article-title":"Retrospective examination of lipid-lowering treatment patterns in a real-world high-risk cohort in the UK in 2014: comparison with the National Institute for Health and Care Excellence (NICE) 2014 lipid modification guidelines","volume":"7","author":"Steen","year":"2017","journal-title":"BMJ Open"},{"key":"10.1016\/j.atherosclerosis.2018.02.024_bib16","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.clinthera.2017.03.001","article-title":"Use of lipid-modifying therapy and LDL-C goal attainment in a high-cardiovascular-risk population in The Netherlands","volume":"39","author":"Kuiper","year":"2017","journal-title":"Clin. Ther."},{"key":"10.1016\/j.atherosclerosis.2018.02.024_bib17","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1093\/eurheartj\/ehr158","article-title":"ESC\/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)","volume":"32","author":"European Association for Cardiovascular Prevention & Rehabilitation","year":"2011","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2018.02.024_bib18","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","article-title":"2016 ESC\/EAS guidelines for the management of dyslipidaemias","volume":"37","author":"Catapano","year":"2016","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2018.02.024_bib19","unstructured":"GAZZETTA UFFICIALE DELLA REPUBBLICA ITALIANA. 2014. Available at: http:\/\/www.gazzettaufficiale.it\/do\/gazzetta\/downloadPdf?dataPubblicazioneGazzetta=20140708&numeroGazzetta=156&tipoSerie=SG&tipoSupplemento=GU&numeroSupplemento=0&estensione=pdf&edizione=0 [Accessed 2 May 2017]."},{"key":"10.1016\/j.atherosclerosis.2018.02.024_bib20","first-page":"240","article-title":"Achieving optimal cholesterol levels in patients with chronic ischemic heart disease: from guidelines to the real world","volume":"16","author":"Cherubini","year":"2015","journal-title":"G.\u00a0Ital. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2018.02.024_bib21","first-page":"167","article-title":"Secondary prevention of coronary heart disease. A survey in an Italian primary care practice","volume":"58","author":"Modesti","year":"2010","journal-title":"Minerva Cardioangiol."},{"key":"10.1016\/j.atherosclerosis.2018.02.024_bib22","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.phrs.2011.06.017","article-title":"Reaching LDL-c targets in high-risk patients requires high-efficacy cholesterol-lowering drugs in more than 50% of cases. The results of the CHECK study","volume":"64","author":"Poli","year":"2011","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.atherosclerosis.2018.02.024_bib23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0095419","article-title":"Can Italian healthcare administrative databases be used to compare regions with respect to compliance with standards of care for chronic diseases?","volume":"9","author":"Gini","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.atherosclerosis.2018.02.024_bib24","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1093\/eurheartj\/eht273","article-title":"Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society","volume":"34","author":"Nordestgaard","year":"2013","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2018.02.024_bib25","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0102146","article-title":"Pattern of statin use in southern Italian primary care: can prescription databases be used for monitoring long-term adherence to the treatment?","volume":"9","author":"Ferrajolo","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.atherosclerosis.2018.02.024_bib26","unstructured":"Istituto Superiore di Sanit\u00e0. Carta del rischio cardiovascolare. Available at: http:\/\/www.cuore.iss.it\/valutazione\/carte.asp. [Accessed January 26, 2017]."},{"key":"10.1016\/j.atherosclerosis.2018.02.024_bib27","series-title":"Note AIFA 204: Revisione delle Note CUF","author":"Agenzia Italiana del Farmaco","year":"2004"},{"key":"10.1016\/j.atherosclerosis.2018.02.024_bib28","doi-asserted-by":"crossref","unstructured":"Organisation for Economic Co-operation and Development. Health at a Glance 2013: OECD Indicators. Paris (France): OECD Publishing. Available at: https:\/\/doi.org\/10.1787\/health_glance-2013-en. [Accessed January 26, 2017].","DOI":"10.1787\/health_glance-2013-en"},{"key":"10.1016\/j.atherosclerosis.2018.02.024_bib29","doi-asserted-by":"crossref","first-page":"A378","DOI":"10.1016\/j.jval.2015.09.798","article-title":"A\u00a0one-year follow-up of patients with acute coronary syndrome (ACS) and diabetes treated with statins: outcomes and health care costs supported by Italian national health service","volume":"18","author":"Maggioni","year":"2015","journal-title":"Value Health"},{"key":"10.1016\/j.atherosclerosis.2018.02.024_bib30","first-page":"A380","article-title":"Epidemiology of patients affected by acute coronary syndrome (ACS) treated with statins for hypercholesterolemia from Italian administrative official databases","volume":"18","author":"Degli Esposti","year":"2015","journal-title":"Value Health"},{"key":"10.1016\/j.atherosclerosis.2018.02.024_bib31","first-page":"273","article-title":"Adherence to statin treatment following a myocardial infarction: an Italian population-based survey","volume":"7","author":"Monaldi","year":"2015","journal-title":"Clinicoecon. Outcomes Res."},{"key":"10.1016\/j.atherosclerosis.2018.02.024_bib32","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s11739-016-1391-0","article-title":"Combination evidence-based therapy is effective in the oldest 'old patients' following myocardial infarction","volume":"11","author":"Di Bari","year":"2016","journal-title":"Intern. Emerg. Med"},{"key":"10.1016\/j.atherosclerosis.2018.02.024_bib33","doi-asserted-by":"crossref","first-page":"270","DOI":"10.2459\/JCM.0b013e328355fae8","article-title":"Lipid-lowering treatment in patients at high cardiovascular risk discharged from an Italian hospital","volume":"14","author":"Spighi","year":"2013","journal-title":"J.\u00a0Cardiovasc. Med."},{"key":"10.1016\/j.atherosclerosis.2018.02.024_bib34","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/1471-2261-11-59","volume":"11","author":"Sanna","year":"2011","journal-title":"BMC Cardiovasc. Disord."},{"key":"10.1016\/j.atherosclerosis.2018.02.024_bib35","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.pcd.2014.04.008","article-title":"Health care delivery in type 2 diabetes. A survey in an Italian primary care practice","volume":"9","author":"Modesti","year":"2015","journal-title":"Prim. Care Diabetes"},{"key":"10.1016\/j.atherosclerosis.2018.02.024_bib36","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1111\/joim.12073","article-title":"Gender differences in cardiovascular disease risk factors, treatments and complications in patients with type 2 diabetes: the RIACE Italian multicentre study","volume":"274","author":"Penno","year":"2013","journal-title":"J.\u00a0Intern. Med."},{"key":"10.1016\/j.atherosclerosis.2018.02.024_bib37","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/j.jacc.2016.01.008","article-title":"Attainment of LDL-cholesterol treatment goals in patients with familial hypercholesterolemia: 5-year SAFEHEART registry follow-up","volume":"67","author":"Perez de Isla","year":"2016","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2018.02.024_bib38","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.atherosclerosis.2009.09.014","article-title":"Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in The Netherlands","volume":"209","author":"Pijlman","year":"2010","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2018.02.024_bib39","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.atherosclerosis.2014.02.021","article-title":"Improvement in LDL-cholesterol levels of patients with familial hypercholesterolemia: can we do better? Analysis of results obtained during the past two decades in 1669 French subjects","volume":"234","author":"Beliard","year":"2014","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2018.02.024_bib40","doi-asserted-by":"crossref","first-page":"A1482","DOI":"10.1016\/S0735-1097(15)61482-6","article-title":"Low LDL-cholesterol target achievement in statin-treated patients in clinical practice in China and Europe: results of the Dyslipidemia International Study (DYSIS)","volume":"65","author":"Gitt","year":"2015","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2018.02.024_bib41","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.atherosclerosis.2016.01.018","article-title":"Lipid lowering drug therapy in patients with coronary heart disease from 24 European countries\u2013findings from the EUROASPIRE IV survey","volume":"246","author":"Reiner","year":"2016","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2018.02.024_bib42","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/1472-6963-14-6","article-title":"The impact of regional co-payment and national reimbursement criteria on statins use in Italy: an interrupted time-series analysis","volume":"14","author":"Damiani","year":"2014","journal-title":"BMC Health Serv. Res."},{"key":"10.1016\/j.atherosclerosis.2018.02.024_bib43","first-page":"3S","article-title":"Role of adherence to long-term drug therapy in patients with cardiovascular disease: an Italian intersocietary consensus document","volume":"15","author":"Volpe","year":"2014","journal-title":"G.\u00a0Ital. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2018.02.024_bib44","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1016\/j.jacc.2015.05.001","article-title":"Are PCSK9 inhibitors the next breakthrough in the cardiovascular field?","volume":"65","author":"Giugliano","year":"2015","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.atherosclerosis.2018.02.024_bib45","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2018.02.024_bib46","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1161\/CIRCULATIONAHA.116.024604","article-title":"Reductions in Atherogenic lipids and major cardiovascular events: a pooled analysis of 10 ODYSSEY trials comparing alirocumab with control","volume":"134","author":"Ray","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2018.02.024_bib47","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1089\/jwh.2015.5282","article-title":"Gender disparities in lipid-lowering therapy in cardiovascular disease: insights from a managed care population","volume":"25","author":"Rodriguez","year":"2016","journal-title":"J.\u00a0Wom. Health (Larchmt)"},{"key":"10.1016\/j.atherosclerosis.2018.02.024_bib48","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.ahj.2009.08.009","article-title":"Low- and high-density lipoprotein cholesterol goal attainment in dyslipidemic women: the Lipid Treatment Assessment Project (L-TAP) 2","volume":"158","author":"Santos","year":"2009","journal-title":"Am. Heart J."},{"key":"10.1016\/j.atherosclerosis.2018.02.024_bib49","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/S0140-6736(14)61368-4","article-title":"Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials","volume":"385","author":"Cholesterol Treatment Trialists","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.atherosclerosis.2018.02.024_bib50","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/clc.22641","article-title":"Patterns and predictors of lipid-lowering therapy in patients with atherosclerotic cardiovascular disease and\/or diabetes mellitus in 2014: insights from a large US managed-care population","volume":"40","author":"Steen","year":"2017","journal-title":"Clin. Cardiol."}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002191501830087X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002191501830087X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T16:23:17Z","timestamp":1762186997000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002191501830087X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4]]},"references-count":50,"alternative-id":["S002191501830087X"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2018.02.024","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Statin utilization and lipid goal attainment in high or very-high cardiovascular risk patients: Insights from Italian general practice","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2018.02.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}